Welcome to our dedicated page for Tyra Biosciences news (Ticker: TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences stock.
Tyra Biosciences develops clinical-stage precision medicines that target Fibroblast Growth Factor Receptor (FGFR) biology. News about TYRA commonly centers on its SNÅP drug-design platform, oral dabogratinib as an FGFR3-selective inhibitor, and pipeline programs in targeted oncology and genetically defined conditions.
Recurring updates include financial results, scientific conference presentations, clinical-study progress in urologic cancers, achondroplasia, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and governance or leadership changes. Company announcements also cover investor-conference participation and program descriptions for TYRA-430 and TYRA-200.
Tyra Biosciences (Nasdaq: TYRA) reported Q1 2026 results and program updates, centered on its oral FGFR3 inhibitor dabogratinib.
The company advanced three Phase 2 studies (SURF303 in LG-UTUC, SURF302 in IR NMIBC, BEACH301 in achondroplasia) with key data readouts expected from August 2026 through 2027.
Q1 cash, cash equivalents and marketable securities were $383.5 million, with runway into 2H 2028.
TYRA raised $147.9 million net via its ATM, grew R&D and G&A expenses, and reported a net loss of $39.3 million.
Tyra Biosciences (Nasdaq: TYRA) announced participation in three investor conferences in May–June 2026: BofA Securities Health Care Conference (virtual fireside chat, May 13, 2026, 10:40 am PT, Las Vegas), TD Cowen Oncology Innovation Summit (virtual fireside chat, May 26, 2026, 2:00 pm ET), and Jefferies Global Healthcare Conference (hybrid, June 3, 2026, 3:45 pm ET, New York).
Access: Live webcasts and replays will be available on the company's For Investors webpage.
Tyra Biosciences (NASDAQ: TYRA) appointed Habib Dable to its Board of Directors on April 17, 2026. Mr. Dable brings over 30 years of biopharma leadership with commercial and global-launch experience, including leadership roles at Bayer and as CEO of Acceleron, which was acquired by Merck in 2021.
The company also said director Gilla Kaplan will conclude her board service at this year’s annual meeting. The appointment is presented as adding commercial expertise to support commercialization plans for dabogratinib across oncology and genetic indications.
Tyra Biosciences (Nasdaq: TYRA) reported Q4 and full‑year 2025 results and outlined its "dabogratinib 3x3" strategy targeting LG‑UTUC, IR NMIBC and achondroplasia. TYRA holds $256.0 million in cash and marketable securities, with a stated runway through at least 2027. Key near‑term clinical catalysts: SURF302 interim data by end 1H 2026 and BEACH301 safety sentinel results in 2H 2026; SURF303 first patient expected in 2026. Full‑year R&D rose to $102.9M and net loss widened to $119.9M.
Tyra Biosciences (NASDAQ: TYRA) announced two poster presentations at the 2026 ASCO Genitourinary (GU) Cancers Symposium, held February 26-28, 2026 in San Francisco.
Posters on dabogratinib (formerly TYRA-300) include ctDNA monitoring in metastatic urothelial cancer (Abstract 809) and a SURF302 Phase 2 trial in non-muscle invasive bladder cancer (TPS886), both presented February 27, 2026 at 11:30 AM–12:45 PM PST. Posters will be posted on TYRA's investor relations website after the presentations.
Tyra Biosciences (Nasdaq: TYRA) will participate in multiple investor conferences between Feb 26 and Mar 12, 2026, including virtual and in-person presentations and one-on-one meetings.
Key events: Oppenheimer Life Sciences (virtual chat) on Feb 26, 2026; TD Cowen (hybrid) on Mar 4, 2026 in Boston; and multiple Miami conferences March 8–12 with webcasts and replays available on the company's investor site.
Armada Hoffler (NYSE: AHH) will report fourth quarter results for the period ending December 31, 2025, and provide projected guidance for 2026 on Monday, February 16, 2026 at ~4:00 PM ET.
Management will host a conference call and webcast on Tuesday, February 17, 2026 at 8:30 AM ET to discuss earnings, guidance, and related information. Dial-in numbers: (+1) 800 549 8228 (toll-free) or (+1) 646 564 2877; conference ID 89782. The call will be available on the company investors page at ArmadaHoffler.com.
A telephonic replay will be available through Thursday, March 19, 2026 via (+1) 888 660 6264 or (+1) 646 517 3975 with passcode 89782. A webcast replay will be accessible for 30 days beginning ~two hours after the call.
Tyra Biosciences (Nasdaq: TYRA) appointed Bhavesh Ashar as Chief Operating Officer (effective immediately) and Heather Faulds as Chief Regulatory Officer (effective December 8, 2025).
Both hires bring senior pharmaceutical experience: Mr. Ashar has 25+ years including chief commercial roles and launches of OGSIVEO and GOMEKLI; Ms. Faulds has 20+ years leading global regulatory strategy and was involved in approvals including SPINRAZA and LYBALVI. They will support advancement of oral dabogratinib through global Phase 2 studies in skeletal dysplasia and urologic cancers and preparation for potential Phase 3 programs.
Tyra Biosciences (Nasdaq: TYRA) announced management will participate in investor events in November–December 2025, including a hybrid presentation at the Jefferies London Healthcare Conference and one-on-one meetings at the 37th Annual Piper Healthcare Conference.
Jefferies presentation: Wednesday, November 19, 2025 at 4:00 PM GMT (hybrid slides & moderated Q&A) in London, UK; a live webcast will be available on Tyra Biosciences' For Investors page and replayed after the event. Piper conference meetings: December 2–4, 2025 in New York, NY.
Tyra Biosciences (Nasdaq: TYRA) reported Q3 2025 results and clinical progress on November 5, 2025. Key clinical updates: TYRA dosed first patients with dabogratinib in BEACH301 (achondroplasia) and SURF302 (FGFR3-altered IR NMIBC), advanced development into LG-UTUC with an IND cleared by the FDA, and expects interim Phase 2 readouts in 2026.
Financials: TYRA held $274.9 million in cash, cash equivalents and marketable securities as of September 30, 2025, providing runway through at least 2027. Q3 R&D was $25.5M, G&A $7.5M, and net loss $29.9M.